rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    JNJ
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Ken Griffin Sells NYC Duplex to Woody Johnson for $58 Million
      Nov 17BloombergJNJ
      Exclusive | Ken Griffin Sells New York City Duplex to Woody Johnson for $58 Million
      Nov 17WSJJNJ
      Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue | The Motley Fool

      J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.

      Nov 17The Motley FoolJNJ
      Eli Lilly Short Interest Rises, Remains Below August Peak
      Nov 17BenzingaJNJLLY
      Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?
      Nov 17Yahoo FinanceJNJ
      Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
      Nov 17Yahoo FinanceJNJ
      Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
      Nov 17Yahoo FinanceJNJ
      The Zacks Analyst Blog Highlights Taiwan, Johnson & Johnson, Palantir, Title and Altigen
      Nov 17Yahoo FinanceJNJPLTR
      Trial lawyer Lanier joins investor lawsuit over J&J's talc disclosures
      Nov 17ReutersJNJ
      Johnson & Johnson Inks $2.2B Deal for Eye Drug Developer Ollin Biosciences
      Nov 16BenzingaJNJ
      Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

      Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.

      Nov 16WSJJNJ
      J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences
      Nov 16Yahoo FinanceJNJ
      Why Is Johnson & Johnson (JNJ) Showcasing New Blood Cancer Data At ASH?
      Nov 16Yahoo FinanceJNJ
      J&J in discussions to buy Ollin Biosciences for up to $3.4B - report

      Johnson & Johnson is in talks to buy Ollin Biosciences for up to $3.4B, including $2.2B upfront and $1.2B in potential milestones.

      Nov 16Seeking AlphaJNJ
      J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
      Nov 16Yahoo FinanceJNJ
      J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says

      Nov 15 () - Johnson & Johnson could announce a deal as soon as Monday ‌to buy Texas-based biotech Ollin Biosciences ‌for up to $3.4 billion, the Financial Times said, citing ​people familiar with the matter.

      Nov 16Yahoo FinanceJNJ
      Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
      Nov 15Financial TimesJNJ
      Johnson & Johnson EVP sells $3.7M in shares after option exercise
      Nov 14Investing.comJNJ
      ETFs Are Buying Johnson & Johnson (JNJ) on Nov. 11
      Nov 13Yahoo FinanceJNJ
      Johnson & Johnson (JNJ) Backs New Cancer Device And Leads $100 Million Depression Bet
      Nov 12Yahoo FinanceJNJ
      Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
      Nov 12Yahoo FinanceJNJ
      Is There A Risk Hiding In Johnson & Johnson Stock's Earnings?
      Nov 12Yahoo FinanceJNJ
      State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Nov. 10
      Nov 12Yahoo FinanceJNJLLYSTT
      These 5 Dividend Aristocrats® Have Raised Payouts for Decades

      Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.

      Nov 12The Globe and MailJNJKO
      Johnson & Johnson Reports Favorable Data For Bipolar Study
      Nov 11BenzingaJNJ
      SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?
      Nov 11Yahoo FinanceJNJVZ
      Is Johnson & Johnson (JNJ) Below Fair Value On Cash Flow?
      Nov 10Yahoo FinanceJNJ
      $300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here’s What It Pays
      Nov 10Yahoo FinanceDUKDUKBJNJPM
      Scotiabank Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)

      Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

      Nov 10The Globe and MailJNJ
      J&J eyes US nod for Caplyta in bipolar mania after second trial win
      Nov 10ReutersJNJ
      Johnson & Johnson’s Caplyta meets endpoints in bipolar mania study
      Nov 10Investing.comJNJ
      Stocks extend recovery from Thursday's sell-off. Plus, new trial data from Lilly, J&J

      Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

      Nov 9CNBCJNJLLY
      Johnson and Johnson stock hits all-time high of 282.03 USD
      Nov 9Investing.comJNJ
      J&J gets into psychedelic treatments with backing of Delix Therapeutics (JNJ:NYSE)
      Nov 9Seeking AlphaJNJ
      What Is Johnson & Johnson (JNJ) Signaling With Two Key Trial Wins?
      Nov 9Yahoo FinanceJNJ
      Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies
      Nov 9BenzingaJNJ
      J&J Backs Psychedelic-Inspired Biotech in $100 Million Round
      Nov 9BloombergJNJ
      Johnson & Johnson’s ICOTYDE Meets Primary Endpoint in Phase 3 Psoriatic Arthritis Trial
      Nov 9Yahoo FinanceJNJ
      ETFs Are Net Sellers of Johnson & Johnson (JNJ) on Nov. 5
      Nov 9Yahoo FinanceJNJ
      J&J prostate cancer combination lowers PSA in small early study (JNJ:NYSE)

      Johnson & Johnson’s prostate cancer immunotherapy showed strong early PSA declines in a small trial.

      Nov 8Seeking AlphaJNJ
      J&J reports patient findings from Sjögren’s drug study
      Nov 8Seeking AlphaJNJ
      Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to Growth
      Nov 8Yahoo FinanceJNJ
      J&J posts trial win for psoriatic arthritis pill (JNJ:NYSE)

      Johnson & Johnson (JNJ) says plaque psoriasis pill Icotyde succeeded in a Phase 3 trial for psoriatic arthritis. Read more here.

      Nov 7Seeking AlphaJNJ
      J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
      Nov 7Yahoo FinanceJNJ
      Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
      Nov 7Yahoo FinanceJNJ
      Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

      Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's disease (SjD), a chronic, systemic autoantibody-driven disease affecting approximately four million people worldwide.1 The results show that mouth dryness is the symptom improvement that matters most to patients,2 complementing previously reported Phase 2 study results on increased saliva production in patients who received nipocalimab.3 This was also the most

      Nov 7Yahoo FinanceJNJ
      4 Stocks I'm Not Selling Even If the Fed Keeps Raising Rates | The Motley Fool

      Some companies will perform pretty well regardless of whether or not interest rates rise.

      Nov 6The Motley FoolJNJ
      First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA Nod
      Nov 6BenzingaJNJ
      Johnson & Johnson wins FDA approval for Rybrevant cancer treatment
      Nov 6Investing.comJNJ
      FDA grants J&J accelerated approval for head and neck cancer treatment
      Nov 5ReutersJNJ

      This is the newest page. Registered accounts read further back.